Chinedu Nweke, MD
Nephrology · Acworth, GANPI 1033341656
Payments from drug & device makers
Across 1,390 payments — averaging $2821.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$1.9M
- CSL Behring$598K
- Eli Lilly$561K
- Acella Pharmaceuticals, LLC$320K
- Novartis$241K
- Vertex$141K
- plus $210K from 18 others
Across 6 payments — averaging $71,005 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$426K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 1,093 | $1,850,431 |
| CSL Behring | 101 | $598,052 |
| Eli Lilly | 6 | $560,550 |
| Acella Pharmaceuticals, LLC | 33 | $320,217 |
| Novartis | 10 | $241,040 |
| Vertex | 2 | $141,017 |
| Hoffmann-la Roche Limited | 33 | $129,939 |
| Romark Laboratories, LC | 1 | $34,860 |
| AstraZeneca(2 entities) | 14 | $27,879 |
| Avion Pharmaceuticals | 2 | $11,050 |
| Amgen(2 entities) | 42 | $5,316 |
| Otsuka America Pharmaceutical, Inc. | 14 | $306 |
| Bayer | 10 | $212 |
| Shield Therapeutics Inc | 6 | $113 |
| Aurinia Pharma U.S., Inc. | 4 | $99 |
| OPKO Pharmaceuticals, LLC | 4 | $72 |
| Calliditas Therapeutics US Inc. | 3 | $69 |
| Novo Nordisk | 3 | $65 |
| Akebia Therapeutics Inc | 2 | $49 |
| Nxstage Medical, Inc. | 2 | $46 |
| Averitas Pharma Inc. | 2 | $46 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Lilly USA, LLC | 1 | $18 |
| Exact Sciences | 1 | $16 |
How this compares
$3,921,482 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Acworth
- James TumlinLawrenceville$19.8M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
- Tamorie SmithColumbus$1.9M
- Barton BrezinaAugusta$1.5M
- Frederic Rahbari OskouiAtlanta$1.5M
- Rajeev ChauhanColumbus$1.1M
- Sagar PanseMacon$1.1M
- Laura MulloyAugusta$891K
- Matthew DiamondAugusta$815K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.